Rhinitis symptoms and quality of life in patients with chronic perennial rhinitis treated with desloratadine

Journal of Laryngology and Otology

Volumn 121, Issue 12, 2007, Pages 1151-1155

  Lam, H C K ^a   Tong, M C F ^a   Van Hasselt, C A ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Antihistamines; Desloratadine; Perennial Allergic Rhinitis

Indexed keywords

DESLORATADINE; DRUG DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST; LORATADINE;

ADULT; ARTICLE; CHINESE; CHRONIC RHINITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DROWSINESS; DRUG EFFICACY; ENDOSCOPY; FATIGUE; FEMALE; HEALTH STATUS; HUMAN; MALE; NASAL PRURITUS; NOSE DISEASE; NOSE EDEMA; NOSE OBSTRUCTION; NOSE POLYP; OCULAR PRURITUS; OPEN STUDY; PERENNIAL RHINITIS; PRESCRIPTION; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RHINORRHEA; SHORT FORM 36; SNEEZING; TREATMENT OUTCOME; XEROSTOMIA; CHRONIC DISEASE; HOSPITALIZATION; MIDDLE AGED;

ADULT; CHRONIC DISEASE; ENDOSCOPY; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LORATADINE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; RHINITIS, ALLERGIC, PERENNIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 40449117170     PISSN: 00222151     EISSN: 17485460     Source Type: Journal    
DOI: 10.1017/S0022215107000059     Document Type: Article

References (15)

1. Naclerio R, Solomon W. Rhinitis and inhalant allergens. JAMA 1997;278:1842-8
2. Berger WE, Schenkel EJ, Mansfield LE. Desloratadine Study Group. Safety and efficacy of desloratadine 5mg in asthma patients with seasonal rhinitis and nasal congestion.. Ann Allergy Asthma Immunol 2002;89:485-91
3. Bachert C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy 2001;56(suppl 65):14-20
4. Corren J, Salmun LM. Quality of life in patients with seasonal allergic rhinitis is improved with desloratadine. Allergy 2000;5:193-4
5. Lebel B, Bousquet J, Morel A, Chanal I, Godard P, Michel FB. Correlation between symptoms and the threshold for release of mediators in nasal secretions during nasal challenge with grass-pollen grains. J Allergy Clin Immunol 1988;5:869-77
6. Ware JE, Snow KK, Kosinski M, Gandek B. SF36 Health Survey - Manual and Intrepretation Guide. Boston: The Health Institute, 1993
7. Lam CLK, Gandek B, Ren XS, Chan MS. Tests of scaling assumptions and construct validity of the Chinese (HK) version of the SF-36 health survey. J Clin Epidemiol 1998;51:1139-47
8. Lund VJ, Kennedy DW. Quantification for staging sinusitis. The Staging and Therapy Group. Ann Otol Rhinol Laryngol (Suppl) 1995; 167(suppl):17-21
9. Genovese A, Patella V, De Crescenzo G, De Paulis A, Spadaro G, Marone G. Loratadine and Desethoxylcarbonylloratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells. Clin Exp Allergy 1997;27:559-67
10. Lippert U, Kruger-Krasagakes S, Moller A, Kiessling U, Czarnetzki BM. Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxyloratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol 1995;4:272-6
11. Kleine-Tebbe J, Josties C, Frank G, Stalleicken D, Buschauer A, Schunack W et al. Inhibition of IgE- and non-IgE-mediated histamine release from from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine. J Allegy Clin Immunol 1994;93:494- 500
12. Vignola AM, Crampette L, Mondain M, Sauvere G, Czarlewski W, Bosquet J et al. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy 1995;50:200-3
13. Geha RS, Meltzer EO. Desloratadine:Anew, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001;107:751-62
14. Molet S, Gosset P, Lassalle P, Czarlewski W, Tonnel AB. Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells. Clin Exp Allergy 1997;27:1167-74
15. Lam CLK, Lauder IJ, Lam TP, Gandek B. Population based norming of the Chinese (HK) version of the SF-36 health survey. Hong Kong Practitioner 1999;21:460-70